← Axogen, Inc. (AXGN) (AXGN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Axogen, Inc. (AXGN) (AXGN)
Electromedical & Electrotherapeutic Apparatus · market cap $2.4B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Axogen (AXGN) is a Alachua, Florida-based commercial-stage medical device/biologics company specializing in surgical solutions for peripheral nerve repair, anchored by its AVANCE Processed Nerve Allograft and complementary connectors and membranes. The company is generating $225M in annual revenue (2025) but remains unprofitable, with a $2.06B market cap and $82.7M in net cash. Its lead clinical catalyst is a Phase 3 trial of its processed nerve allograft in peripheral nerve discontinuities, with the next visible corporate event being an August 4, 2026 earnings release.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Processed Nerve Allograft (human) | Phase 3 | Peripheral Nerve Discontinuities |
Price & technical context
3-month
-13.0%
6-month
+18.9%
12-month
+123.8%
52-wk range
$15.59–$51.73
vs 50-day MA
-12.9%
vs 200-day MA
+2.6%
Realized vol
53.8%
Max drawdown
-53.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AXGN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.